LIVE PRICE LOG
24hrdoc$129unchangedAgelessRx$99unchangedAlan$125unchangedAlloy$169unchangedAltru Telehealth$289unchangedaltRx$199unchangedAM Rx$151unchangedAmble Health$135unchangedAmie$151unchangedBelle$93unchangedBioverse$129unchangedBliv$116unchangedbmiMD$99unchangedBodybuilding Health+$179unchangedCalibrate$199unchangedClover Meds$77▼ downCora Health$99▼ downCurex$49unchangedD&H Medical Center$230unchangedDirectMeds$249unchangedDrMedHealth$199unchangedDudeMeds$196unchangedElevated Health$196unchangedEmbody$49unchangedEmerge Weight Loss$224unchangedEnhance.MD$112unchangedEverPrime$214unchangedFancy Meds$199unchangedFifty 410$149.50▲ upFitish$179unchangedFitRx$151unchangedForm Health$299unchangedFound$79unchangedFridays$99unchangedFWD$99unchangedGala$69unchangedGenesis Health$91.67▼ downGobyMeds$93unchangedGoodGirlRX$134unchangedGoodLife Health$299unchangedGoodRx for Weight Loss$119unchangedHarper Meds$149unchangedHealthon$183▲ upHealthRX$105unchangedHealthy Male$149unchangedHenry Meds$179unchangedHers$149unchangedHims$149unchangedHone Health$160unchangedHumeCare+$199unchangedHydraMed$399unchangedIvím Health$140▲ upIVY RX$197unchangedJoi + Blokes$199unchangedJoin Josie$189unchangedJRNYS$89unchangedJulyMD$197unchangedKin Meds$149unchangedLemonaid Health$49unchangedLevity$1,199unchangedLifeMD$149unchangedLillyDirect$299unchangedLumiMeds$89unchangedMaximus$99.99▼ downMeasured$49unchangedMEDGm$169▼ downMedica Weight Loss$99▼ downMEDVi$299unchangedMint Med$159unchangedMochi Health$49unchangedMomentum Health$299unchangedMyDrHank$171unchangedNativeMed$149unchangedNewSelf$99.97▼ downNexlife$95▼ downNoom (Noom Med)$179unchangedNovoCare Pharmacy$149unchangedOak$109unchangedOrderlyMeds$149unchangedPallas Health$139▼ downPeaks$190unchangedPeterMD$149▲ upPharmaZee$99unchangedPlexusDx$99unchangedPlushCare$19.99unchangedPremium Health$275unchangedReady Med$199unchangedRefills$99unchangedRemedy Meds$299▲ upRo (Ro Body)$74unchangedRoenRx$135unchangedRxSpan MD$249unchangedSesame Care$59unchangedShed$199unchangedSnagRx$69unchangedSprout Health$149▲ upStrut Health$99unchangedtelos rx$99unchangedThrivelab$175unchangedTMates$249unchangedTrimi$99▼ downTrimRx$299unchangedTRYM Health$95.83▼ downTuyo Health$155unchangedTyde Wellness$113▼ downVillas Health$179unchangedWeightCare$215unchangedWeightWatchers Clinic$74unchangedWellmedr$41unchangedWellorithm$247unchangedWillow$299unchangedYucca Health$69unchangedZealthy$135unchangedZeuss$125unchanged24hrdoc$129unchangedAgelessRx$99unchangedAlan$125unchangedAlloy$169unchangedAltru Telehealth$289unchangedaltRx$199unchangedAM Rx$151unchangedAmble Health$135unchangedAmie$151unchangedBelle$93unchangedBioverse$129unchangedBliv$116unchangedbmiMD$99unchangedBodybuilding Health+$179unchangedCalibrate$199unchangedClover Meds$77▼ downCora Health$99▼ downCurex$49unchangedD&H Medical Center$230unchangedDirectMeds$249unchangedDrMedHealth$199unchangedDudeMeds$196unchangedElevated Health$196unchangedEmbody$49unchangedEmerge Weight Loss$224unchangedEnhance.MD$112unchangedEverPrime$214unchangedFancy Meds$199unchangedFifty 410$149.50▲ upFitish$179unchangedFitRx$151unchangedForm Health$299unchangedFound$79unchangedFridays$99unchangedFWD$99unchangedGala$69unchangedGenesis Health$91.67▼ downGobyMeds$93unchangedGoodGirlRX$134unchangedGoodLife Health$299unchangedGoodRx for Weight Loss$119unchangedHarper Meds$149unchangedHealthon$183▲ upHealthRX$105unchangedHealthy Male$149unchangedHenry Meds$179unchangedHers$149unchangedHims$149unchangedHone Health$160unchangedHumeCare+$199unchangedHydraMed$399unchangedIvím Health$140▲ upIVY RX$197unchangedJoi + Blokes$199unchangedJoin Josie$189unchangedJRNYS$89unchangedJulyMD$197unchangedKin Meds$149unchangedLemonaid Health$49unchangedLevity$1,199unchangedLifeMD$149unchangedLillyDirect$299unchangedLumiMeds$89unchangedMaximus$99.99▼ downMeasured$49unchangedMEDGm$169▼ downMedica Weight Loss$99▼ downMEDVi$299unchangedMint Med$159unchangedMochi Health$49unchangedMomentum Health$299unchangedMyDrHank$171unchangedNativeMed$149unchangedNewSelf$99.97▼ downNexlife$95▼ downNoom (Noom Med)$179unchangedNovoCare Pharmacy$149unchangedOak$109unchangedOrderlyMeds$149unchangedPallas Health$139▼ downPeaks$190unchangedPeterMD$149▲ upPharmaZee$99unchangedPlexusDx$99unchangedPlushCare$19.99unchangedPremium Health$275unchangedReady Med$199unchangedRefills$99unchangedRemedy Meds$299▲ upRo (Ro Body)$74unchangedRoenRx$135unchangedRxSpan MD$249unchangedSesame Care$59unchangedShed$199unchangedSnagRx$69unchangedSprout Health$149▲ upStrut Health$99unchangedtelos rx$99unchangedThrivelab$175unchangedTMates$249unchangedTrimi$99▼ downTrimRx$299unchangedTRYM Health$95.83▼ downTuyo Health$155unchangedTyde Wellness$113▼ downVillas Health$179unchangedWeightCare$215unchangedWeightWatchers Clinic$74unchangedWellmedr$41unchangedWellorithm$247unchangedWillow$299unchangedYucca Health$69unchangedZealthy$135unchangedZeuss$125unchanged
GLP-1 Dossier

The record

Every action on file

88 regulatory or legal actions against 78 of the 128 providers on this site. Each links to the primary document — an FDA letter, a court filing, a regulator’s own announcement. Nothing here is sourced from a blog.

Actions on file
88
Companies involved
78 of 128
Most recent
July 2026
Busiest month
26 in February 2026
An action against a company is not proof that any particular customer was harmed, and it is not a statement that a company is a scam. Most of these concern how a product was marketed. Read the document and decide for yourself — that is why every one of them is linked.

By date

The timeline

Newest first, grouped by the month the action was published or filed.

July 2026 3 actions

Hims — The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.

Primary source →

Hers — The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven. Hers is the same legal entity.

Primary source →

Willow — Reopened NAD matter closed after Willow Health Services voluntarily discontinued claims that its compounded semaglutide was proven to support weight loss, delivered results comparable to FDA-approved semaglutide, and produced effective weight loss without diet or exercise.

Primary source →

June 2026 25 actions

Altru Telehealth — FDA warning letter to Altru Telehealth, LLC alleging its website described compounded semaglutide and tirzepatide as having "FDA-approved active ingredients" and offering "the same results" as branded drugs, and described compounding pharmacies as "FDA approved" and "FDA licensed", which misbranded the products.

Primary source →

altRx — FDA warning letter to Trinity HealthCare Supply, LLC dba altRx alleging its website labelling identified "altRx" on pictured compounded semaglutide and tirzepatide labels, suggesting altRx was the compounder when it was not, and that claims such as "clinically proven weight loss" represented the compounded products as FDA-approved or evaluated for safety and effectiveness.

Primary source →

AM Rx — FDA warning letter to FitRX, LLC dba AM RX alleging its compounded product labels bore "AM Rx" as though it were the manufacturer, and that describing the compounded drugs as containing "the active ingredient in FDA-approved medications like Wegovy and Ozempic" misrepresented them as FDA-approved.

Primary source →

Amie — FDA warning letter to Amie Health, Inc. dba Amie alleging its website made false or misleading claims about compounded semaglutide and tirzepatide, including "All our treatments use FDA-approved active ingredients", and that product labels displaying "amie" suggested Amie was the compounder when it was not.

Primary source →

Clover Meds — FDA warning letter to Clover Meds LLC alleging its compounded semaglutide and tirzepatide were misbranded because the labels carried the "Clover Meds" name, suggesting it was the manufacturer, and because its website described products as coming from "FDA-licensed Facilities".

Primary source →

D&H Medical Center — FDA warning letter to D&H Medical Services alleging that marketing its compounded products as the "Same ingredient as Ozempic", "Same ingredient as Rybelsus" and "Same ingredient as Mounjaro" represented them as FDA-approved or evaluated for safety and effectiveness when they were not.

Primary source →

DrMedHealth — FDA warning letter to Public Health Solution LLC dba DrMedHealth alleging that website claims describing its compounded products as having the "Same active ingredient as Ozempic" and "Same active ingredient as Mounjaro" misrepresented compounded drugs as FDA-approved or evaluated for safety and effectiveness.

Primary source →

Eden — FDA warning letter to Eden Health International, Inc. dba Eden (MARCS-CMS 728279).

Primary source →

Ezra — FDA warning letter to Ezra Holdco LLC dba Ezra alleging its website labelling for compounded semaglutide and tirzepatide identified "Ezra" on the pictured label, suggesting Ezra was the compounder of those drugs when it was not.

Primary source →

Fitish — FDA warning letter to FITISH alleging that "FITISH" appearing on compounded product labels suggested it was the manufacturer, and that statements such as "Semaglutide is the active ingredient in ozempic" and "Tirzepatide is the active ingredient in Mounjaro and Zepbound" misrepresented the compounded drugs as FDA-approved.

Primary source →

Harper Meds — FDA warning letter to Nexus Health Solutions LLC dba Harper Meds alleging that "Harper Meds" on compounded product labels suggested it was the manufacturer, that the claim "Same active ingredient as Ozempic & Wegovy" implied FDA approval, and that describing its sources as "FDA-licensed 503A Outsourcing Facilities" was false because compounding facilities are not FDA-licensed.

Primary source →

HydraMed — FDA warning letter to HydraMed IV LLC dba HydraMed alleging that "HydraMed" on compounded semaglutide and tirzepatide labels suggested it was the manufacturer, and that its website claim that products came from an "FDA-approved pharmacy" was false because compounding pharmacies and outsourcing facilities are not FDA-approved or FDA-licensed.

Primary source →

Joi + Blokes — FDA warning letter to Joi and Blokes alleging it misbranded compounded semaglutide and tirzepatide by presenting them as equivalent to FDA-approved products such as Ozempic and Wegovy, and by displaying the Joi + Blokes name on labels of drugs it did not compound.

Primary source →

Maximus — FDA warning letter to Maximus Health, Inc. dba Maximus alleging its website made false or misleading claims about compounded semaglutide and tirzepatide, including "Proven to lose weight effectively" and references to "FDA approved pharmacies" that represented the compounded products as FDA-approved or evaluated for safety and effectiveness.

Primary source →

Medica Weight Loss — FDA warning letter to Medica Weight Loss alleging it misbranded compounded semaglutide and tirzepatide by implying FDA approval, describing its compounding source as an "FDA-approved pharmacy", and putting its own branding on labels of drugs it did not compound.

Primary source →

Mint Med — FDA warning letter to Glow Medispa, LLC dba Mint Med alleging its website labelling identified "Mint Med" on pictured compounded semaglutide and tirzepatide labels, suggesting Mint Med was the compounder of those drugs when it was not.

Primary source →

Momentum Health — FDA warning letter to Momentum Health 360 dba Momentum Health alleging its website labelling identified "Momentum Health" on pictured compounded semaglutide, tirzepatide and liraglutide labels, suggesting it was the compounder when it was not, and that claims including "Same active ingredient in Mounjaro and Zepbound" and describing compounding facilities as "FDA-licensed" were false or misleading.

Primary source →

NativeMed — FDA warning letter to NativeMed LLC alleging it misbranded compounded tirzepatide by displaying its own logo on labels of drugs it did not compound, and marketed compounded semaglutide as containing "The same active ingredient in Ozempic and Wegovy", implying FDA approval it does not have.

Primary source →

Nexlife — FDA warning letter to Nexlife Inc. dba Nexlife alleging its website labelling identified "Nexlife" on pictured compounded semaglutide and tirzepatide labels, suggesting Nexlife was the compounder of those drugs when it was not, and that its representations about the products were false or misleading.

Primary source →

NOVARX — FDA warning letter to Nova Vascular LLC dba NOVARX alleging it misbranded compounded semaglutide and tirzepatide by advertising "access to the same active ingredient found in Ozempic", claiming products came from "FDA Approved Pharmacies", and displaying "NOVA RX" on labels of drugs it did not compound.

Primary source →

OrderlyMeds — FDA warning letter to OrderlyMeds LLC dba OrderlyMeds (MARCS-CMS 728291), part of the June 2026 round over compounded GLP-1 marketing.

Primary source →

Ready Med — FDA warning letter to Ready Med alleging it misbranded compounded semaglutide and tirzepatide by marketing them as "The same active ingredient in Mounjaro and Zepbound" and "The same active ingredient in Ozempic and Rybelsus", claiming they came from an "FDA licensed compounding facility", and displaying "Ready Med" on labels of drugs it did not compound.

Primary source →

RoenRx — FDA warning letter to Roen Health, Inc. dba RoenRx alleging it misbranded compounded semaglutide by displaying "RoenRx" on labels of a drug it did not compound, and by stating that "Semaglutide is the active ingredient in FDA-approved medications like Wegovy and Ozempic", which the agency said implies FDA approval the compounded product lacks.

Primary source →

Thrivelab — FDA warning letter to Thrivelab Co. dba Thrivelab alleging its website labelling identified "thrivelab" on pictured compounded semaglutide labels, suggesting Thrivelab was the compounder when it was not, and that claims such as "Same active ingredient as Wegovy and Ozempic" and "clinically proven to work" represented the compounded product as FDA-approved or evaluated for safety and effectiveness.

Primary source →

VivioMD — FDA warning letter to VivioMD Group LLC alleging it misbranded compounded semaglutide and tirzepatide because the product labels pictured on its website identify "VivioMD" as the compounder when it is not, and that the products are unapproved new drugs.

Primary source →

May 2026 2 actions

Noom (Noom Med) — NAD (BBB National Programs) decision, challenged by Eli Lilly, recommended Noom discontinue or modify its 'Microdose GLP-1Rx' claims for lack of support that the lower dose delivers a measurable health benefit; Noom disagreed but agreed to comply.

Primary source →

AgelessRx — AgelessRx filed a notice with the California Attorney General reporting that between 17 and 22 April 2026 an unauthorised party accessed help-desk tickets containing customer names together with date of birth, health diagnosis or condition, medications and other treatment information, and offered twelve months of Experian credit monitoring in response. This is a breach the company disclosed about itself, not an enforcement action against it.

Primary source →

March 2026 2 actions

Hims — Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.

Primary source →

Hers — Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.

Primary source →

February 2026 26 actions

Willow — Eli Lilly sued Willow Health Services, Inc. in the Central District of California on 23 April 2025 (No. 2:25-cv-03570) over compounded tirzepatide. The case was dismissed with prejudice on 3 February 2026 for failure to establish Lanham Act standing — the court held the prescribing physician, not Willow's advertising, was the proximate cause of any lost sales — with no ruling on whether the marketing was misleading. Lilly has appealed to the Ninth Circuit (No. 26-1317).

Primary source →

24hrdoc — FDA warning letter to 24HrDoc, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the 24HrDoc name, representing it as the manufacturer when it was not, and because website claims such as "Same ingredients as: Ozempic and Wegovy" implied the products were FDA-approved.

Primary source →

Alan — FDA warning letter to Alan Health Technologies Inc. alleging it misbranded compounded semaglutide and tirzepatide, stating that the representations on its website that Alan is the compounder of these drug products are false or misleading, and that the products appear not to meet the conditions for compounded-drug exemptions under sections 503A or 503B.

Primary source →

Belle — FDA warning letter to Belle Health LLC alleging it misbranded compounded semaglutide and tirzepatide because, in the letter's words, the products displayed on its website identify "Belle" on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not.

Primary source →

Bliv — FDA warning letter to Bliv Wellness LLC alleging that the compounded semaglutide and tirzepatide products shown on its website display "Bliv" on the pictured label, suggesting Bliv is the compounder of those drugs when in fact it is not, making the representations false or misleading and the products misbranded.

Primary source →

BluefitMD — FDA warning letter to BluefitMD alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the BluefitMD name, representing it as the compounder when it was not, and because website claims such as "Compounded Semaglutide (the same active ingredient as Ozempic and Wegovy)" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

Primary source →

Fifty 410 — FDA warning letter to Aspen Aesthetics dba Fifty 410 alleging that the compounded semaglutide and tirzepatide products on its website identify "Fifty 410" on the pictured label, suggesting Fifty 410 is the compounder when it is not, and that its "clinically proven ingredients" claim implies the products were FDA-approved or evaluated for safety and effectiveness when they were not.

Primary source →

FitRx — FDA warning letter to FitRX, LLC dba FitRx alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the FitRx name, representing it as the compounder when it was not, and because website claims such as "semaglutide (active ingredient in Wegovy)" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

Primary source →

Genesis Health — FDA warning letter to Genesis Health International Inc. alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Genesis name, representing it as the manufacturer when it was not, and because website claims such as "Contains the same active ingredient as Ozempic and Wegovy" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

Primary source →

GoodGirlRX — FDA warning letter to Good Girl LLC dba GoodGirlRX alleging it misbranded compounded semaglutide and tirzepatide by displaying "GoodGirlRX" on the pictured labels, suggesting it was the compounder when it was not, and by website statements including "FDA-approved meds" and "Clinically proven GLP-1 results", which the agency said imply FDA approval the compounded products do not have.

Primary source →

Ivím Health — FDA warning letter to Ivim Services LLC dba Ivim (MARCS-CMS 721816), part of the February 2026 telehealth action over compounded GLP-1 marketing.

Primary source →

Join Josie — FDA warning letter to Join Josie alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Join Josie name, representing it as the sole manufacturer when it was not, and because claims such as "The same active ingredient found in the FDA-approved brand Wegovy" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

Primary source →

Kin Meds — FDA warning letter to Kin Meds alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the Kin Meds name, representing it as the manufacturer when it was not, and because claims such as "Same Active Ingredient as common brands" implied the compounded products had been FDA-approved or evaluated for safety and effectiveness.

Primary source →

Levity — FDA warning letter to Levity Inc. alleging it misbranded compounded semaglutide and liraglutide by displaying "Levity" on the pictured labels, suggesting Levity was the compounder when it was not, and by website claims such as "The same ingredient as Ozempic + Wegovy" and "The power of Saxenda" that the agency said imply FDA approval the compounded products do not have.

Primary source →

Measured — FDA warning letter to Better Health Labs, Inc. dba Measured alleging it misbranded compounded semaglutide and tirzepatide by displaying "Measured" on the pictured labels, suggesting Measured was the compounder when it was not, and by advertising products with "the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro", which the agency said implies FDA approval the compounded products do not have.

Primary source →

MEDVi — FDA warning letter to MEDVi, LLC dba MEDVi (MARCS-CMS 721455) alleging the products carried MEDVi branding that falsely suggested MEDVi was the compounder, that claims such as 'same active ingredient as Wegovy and Ozempic' implied FDA approval, and that the products were misbranded under FD&C Act sections 502(a) and 502(bb), with seizure, injunction and border detention warned as possible consequences.

Primary source →

NewSelf — FDA warning letter to NewSelf Limited alleging its compounded semaglutide and tirzepatide were misbranded because the labels bore the NewSelf name, representing it as the manufacturer when it was not, and because website claims such as "Same active ingredient as Ozempic & Wegovy" and references to "FDA-approved use" implied the compounded products had been FDA-approved.

Primary source →

Peaks — FDA warning letter to Peaks Curative, LLC alleging it misbranded compounded semaglutide by displaying "Peak Now" on the pictured label, suggesting it was the compounder when it was not, and by website statements including "This FDA-approved treatment promotes safe, effective weight loss" and "Clinically proven to aid in significant weight loss", which the agency said imply FDA approval the compounded products do not have.

Primary source →

PharmaZee — FDA warning letter to PharmaZee alleging its website's compounded semaglutide and tirzepatide labels displayed the PharmaZee name, suggesting PharmaZee is the compounder when it is not, and that claims such as "clinically proven medications" and "Same active ingredient as Ozempic and Wegovy" imply the products were FDA-approved or evaluated for safety and effectiveness when they were not.

Primary source →

Premium Health — FDA warning letter to Premium Health Management Inc. alleging its website's compounded semaglutide and tirzepatide labelling identified Premium Health as the compounder when it is not, and that website claims referencing Ozempic, Wegovy and Mounjaro and describing the products as "generic compounded medication" imply FDA approval or evaluation that has not occurred.

Primary source →

Refills — FDA warning letter to Refills Health, LLC alleging its website's compounded semaglutide labelling displayed the Refills Health name, suggesting it is the compounder when it is not, and that claims including "clinically proven" and "the same active ingredient found in certain FDA approved treatments" imply the products were FDA-approved or evaluated for safety and effectiveness when they were not.

Primary source →

SkinnyRx — FDA warning letter to Lean Rx, Inc. dba SkinnyRx alleging it misbranded compounded semaglutide and tirzepatide by displaying "SkinnyRx" on the pictured labels, suggesting SkinnyRx was the compounder when it was not, and by website statements including "Get access to the same active ingredient as name-brand GLP-1 medications" and "It contains the same active ingredient as FDA-approved medications", which the agency said imply FDA approval the compounded products do not have.

Primary source →

Strut Health — FDA warning letter to Strut Health, LLC dba Strut (MARCS-CMS 721448).

Primary source →

Thrive Health Solutions — FDA warning letter to Thrive Health and Wellness, LLC dba Thrive Health Solutions alleging its sterile drug products, including NAD+ injection and MEGALean tirzepatide injections, were prepared, packed or held under insanitary conditions — citing aseptic operations conducted outside a certified ISO 5 area, personnel who had never performed media fills, non-sterile gloves with exposed hair and skin, carpeted flooring and failure to use a sporicidal agent — and that the products are unapproved new drugs and misbranded for lacking adequate directions for use.

Primary source →

WeightCare — FDA warning letter to Weightless Medical LLC dba WeightCare alleging it misbranded compounded semaglutide and tirzepatide, stating that the representations on its website that WeightCare is the compounder of these drug products are false or misleading, and that the misbranded products were introduced into interstate commerce.

Primary source →

Zeuss — FDA warning letter to Zeuss LLC alleging its compounded tirzepatide was misbranded because the label bore the Zeuss name, representing it as the compounder when it was not, and because website statements including "It is FDA approved and clinically proven to work treatment for weight loss" implied FDA approval the compounded product does not have.

Primary source →

December 2025 1 action

Willow — The National Advertising Division, on a challenge by Novo Nordisk, recommended on 4 December 2025 that Willow Health Services discontinue or modify health claims for its compounded semaglutide products. Willow declined to provide a compliance statement, and NAD referred the matter to regulatory authorities and to the platforms carrying the advertising.

Primary source →

September 2025 19 actions

Hims — FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.

Primary source →

Hers — FDA warning letter to Hims & Hers Health, Inc. dba Hers (MARCS-CMS 716825) over compounded GLP-1 marketing.

Primary source →

Bioverse — FDA warning letter to Bioverse, Inc. alleging claims that its compounded products contained "the same active ingredient as Ozempic and Wegovy" or "Mounjaro and Zepbound" implied they were the same as FDA-approved products, making them misbranded.

Primary source →

Curex — FDA warning letter to Curex alleging its marketing of compounded semaglutide and tirzepatide — including "clinically proven success" and "the same active ingredients as Ozempic or Mounjaro" — implied its products were the same as FDA-approved drugs, making them misbranded.

Primary source →

DirectMeds — FDA warning letter to directmeds.com, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because claims that the products "contain the same active ingredient as branded" medications and are an "effective and budget-friendly alternative" implied equivalence to FDA-approved drugs.

Primary source →

Elevated Health — FDA warning letter to Elevate Your Wellness LLC dba Elevated alleging its compounded semaglutide and tirzepatide were misbranded because claims that they "contain the same active ingredient as the branded medications" implied equivalence to FDA-approved drugs.

Primary source →

Fancy Meds — FDA warning letter to Fancy Meds, LLC alleging its compounded semaglutide and tirzepatide were misbranded because website claims that the products contained "the same active ingredient as" Ozempic, Wegovy, Mounjaro and Zepbound implied equivalence to FDA-approved drugs.

Primary source →

FWD — FDA warning letter to FWD Care, Inc. alleging claims such as "Same active ingredient in Mounjaro and Zepbound" for its compounded semaglutide and tirzepatide implied its products were the same as FDA-approved drugs, making them misbranded.

Primary source →

Healthon — FDA warning letter to Healthon Inc. alleging claims such as "Same active ingredient as Wegovy and Ozempic" and "Clinically proven weight loss" implied its compounded semaglutide and tirzepatide were the same as FDA-approved products, making them misbranded.

Primary source →

Healthy Male — FDA warning letter to Healthy Male alleging its compounded tirzepatide was misbranded because claims including "Clinically shown to support 15-22% average body weight reduction" and "Clinically proven to deliver sustainable results" implied the compounded product was the same as an FDA-approved product.

Primary source →

JulyMD — FDA warning letter to JulyMD alleging claims that its compounded semaglutide had "the same active ingredient as Wegovy and Ozempic" and offered "the same effective ingredient but at a fraction of the price" implied its product was the same as an FDA-approved drug, making it misbranded.

Primary source →

LillyDirect — FDA warning letter to Eli Lilly and Company (MARCS-CMS 716485) finding that the company's participation in an ABC primetime special created a misleading impression regarding the safety of Zepbound and Mounjaro, and misbranded those drugs.

Primary source →

LumiMeds — FDA warning letter to Lumimeds alleging claims that its compounded products contained "the same active ingredient as the brand name medications" and that "GLP-1 was FDA-approved in 2017" implied its unapproved compounded drugs were the same as FDA-approved products, making them misbranded.

Primary source →

NovoCare Pharmacy — FDA warning letter to Novo Nordisk, Inc. (MARCS-CMS 716495) finding that the same ABC primetime special minimised and omitted risk information, creating a misleading impression regarding the safety of Wegovy, Ozempic and Victoza.

Primary source →

Remedy Meds — FDA warning letter to Remedy Meds alleging website claims such as "Semaglutide (Compounded) Same active ingredient as Ozempic and Wegovy" and "Tirzepatide (Compounded) Same active ingredient as Mounjaro and Zepbound" implied its compounded products were the same as FDA-approved drugs, making them misbranded.

Primary source →

Sprout Health — FDA warning letter to Sprout Health Partners LLC alleging its compounded semaglutide and tirzepatide marketing was false or misleading — citing the claim that "GLP-1 medications are FDA-approved and backed by extensive clinical research" — making the products misbranded.

Primary source →

TRYM Health — FDA warning letter to TRYM Health, Inc. alleging website claims including "Clinically Proven to Work", "Contains the same active ingredient as Mounjaro and ZepBound" and "Contains the same active ingredient as Ozempic and Wegovy" implied its compounded products were the same as FDA-approved drugs, making them misbranded.

Primary source →

Tuyo Health — FDA warning letter to Tuyo Health, Inc. alleging its compounded semaglutide and tirzepatide were misbranded because website claims such as "Same active as Wegovy and Ozempic" and "Same active ingredient as Zepbound and Mounjaro" implied equivalence to FDA-approved drugs.

Primary source →

Villas Health — FDA warning letter to Las Villas Health Care LLC dba Villas Health alleging its compounded semaglutide and compounded sildenafil were misbranded because claims that the semaglutide "contains the same active ingredient as Ozempic and Wegovy" and that the sildenafil was "the active ingredient in Viagra" with clinical proof for female sexual arousal disorder implied equivalence to FDA-approved drugs.

Primary source →

August 2025 1 action

Mochi Health — Novo Nordisk sued Mochi Health Corp. and its affiliated medical practices in the Northern District of California on 4 August 2025 (No. 5:25-cv-06563), alleging false advertising and unlawful mass compounding of semaglutide, including converting standard doses to non-standard ones and adding vitamin B12; allegations unproven.

Primary source →

June 2025 1 action

Hims — Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.

Primary source →

May 2025 1 action

bmiMD — Novo Nordisk A/S and Novo Nordisk Inc. sued MEDCCM, Inc. (the corporate operator of bmiMD) in the Eastern District of New York on 21 May 2025 (No. 2:25-cv-02846), asserting Lanham Act trademark infringement claims over its marketing of compounded GLP-1 products. As of mid-2026 the case remained pending before Judge Joan M. Azrack following briefing on MEDCCM's motion to dismiss; allegations unproven.

Primary source →

April 2025 3 actions

Mochi Health — Eli Lilly sued Mochi Health Corp. in the Northern District of California on 23 April 2025 (No. 3:25-cv-03534) over compounded tirzepatide combined with additives including niacinamide, pyridoxine and glycine. In October 2025 the court granted Mochi's motion to dismiss with leave to amend, holding Lilly had not established standing on reputational harm alone.

Primary source →

Fella Health — Eli Lilly and Company filed a federal Lanham Act trademark infringement and false advertising lawsuit against Aios, Inc. d/b/a Fella Health and Delilah, Fella Medical Group P.A., and Fella Medical Group P.C. in the U.S. District Court for the Northern District of California (Case No. 4:25-cv-03535) over the marketing of compounded tirzepatide; Fella Health subsequently announced it resolved the legal dispute with Eli Lilly and immediately ceased advertising compounded GLP-1 offerings.

Primary source →

Henry Meds — Eli Lilly sued Adonis Health, Inc. d/b/a Henry Meds in the Northern District of California on 23 April 2025 (No. 4:25-cv-03536) over its marketing of compounded tirzepatide against Mounjaro and Zepbound. In September 2025 the court dismissed Lilly's safety and efficacy claims and allowed its personalisation claims to proceed.

Primary source →

March 2025 1 action

Mochi Health — The Washington State Pharmacy Quality Assurance Commission issued a Limited Stop Service order on 13 March 2025 against Aequita Pharmacy LLC of Kirkland, Washington — reported to compound for Mochi Health — barring it from compounding or dispensing compounded products in the state, citing untrained and unqualified staff performing sterile compounding, inadequate supervision, and failure to follow sterile compounding procedures.

Primary source →

November 2024 1 action

Zealthy — In United States v. Cerebral, Inc., Zealthy, Inc., Gronk, Inc., and Kyle Robertson (S.D. Fla. Case No. 1:24-cv-21376), the Department of Justice and Federal Trade Commission filed a First Amended Complaint naming Zealthy, Inc. and its founder Kyle Robertson alongside Cerebral, alleging deceptive subscription enrollment, hidden medication charges on top of membership fees, and obstructive cancellation practices across Zealthy’s weight-loss and telehealth programs; DOJ subsequently moved for an immediate asset freeze and temporary receivership against Zealthy.

Primary source →

August 2024 1 action

MyDrHank — Novo Nordisk Inc. sued Dr. Hank, LLC (then doing business as 247 Health alongside Dunklau Pharmacy Holdings, LLC d/b/a Midtown Express Pharmacy) in the Middle District of Tennessee on 30 May 2024 (No. 3:24-cv-00667) for Lanham Act false advertising and unfair competition over unapproved compounded semaglutide. On 13 August 2024 the court entered a Final Judgment and Permanent Injunction on Consent permanently enjoining Dr. Hank, LLC from marketing or selling unapproved compounded semaglutide drugs unless it notifies Novo Nordisk and engages in good-faith discussions regarding legal compliance.

Primary source →

July 2022 1 action

Noom (Noom Med) — Nichols et al. v. Noom Inc., No. 1:20-cv-03677 (S.D.N.Y.) — a consolidated class action over auto-enrolment and auto-renewal practices, in which Geraldine Mahood was a named plaintiff — received final approval on 12 July 2022 of a settlement establishing a $56 million gross settlement fund plus reforms to Noom's enrolment and cancellation practices.

Primary source →

By provider

Who has the most on record

The eight companies with the largest files. Every provider with anything on record is marked in the table on the front page.

HimsFDA-approved4 actions

From $149/mo

HersFDA-approved3 actions

From $149/mo

Mochi HealthBoth3 actions

From $79/mo

WillowCompounded3 actions

From $299/mo

Noom (Noom Med)Both2 actions

From $179/mo

24hrdocCompounded1 action

From $129/mo

AgelessRxCompounded1 action

From $99/mo

AlanBoth1 action

From $125/mo

Why so much of this happened at once

Between September 2025 and March 2026 the FDA issued roughly 85 warning letters to telehealth companies selling compounded GLP-1s. The objection was rarely the compounding itself, which is legal. It was the marketing: describing a compounded drug as a generic version of, or the same as, an approved one; implying FDA approval; or advertising the drug under the telehealth company’s own brand without saying where it came from.

In February 2026 the agency went further and moved to restrict the active ingredients used in non-approved compounded GLP-1 products. That is why several companies on this site now supply FDA-approved medication when a year ago they did not — and why a price you saw quoted in 2025 may not exist any more.

Letters addressed to a pharmacy rather than to a telehealth brand are kept out of the 88 actions above. The most recent one on our record is FDA warning letter 738238 of 18 September 2026 to Empower Pharmacy (Houston, TX), a fulfillment partner named by several providers here: what that letter says and who names Empower →

Long-form provider files

Full price tables, terms and records

Every plan length, the refund and cancellation terms, named pharmacies, review-site links and each regulatory action with its primary document. These 6 providers pay us a referral commission if you sign up through our links; ordered by lowest verified monthly price only.

Provider fileSema. /moTirz. /moActions on fileLinks
Embody$49$99NoneRead the dossier →Embody site ↗
Belle$93$1491Read the dossier →Belle site ↗
PlexusDx$99$129NoneRead the dossier →PlexusDx site ↗
MEDGm$169$269NoneRead the dossier →MEDGm site ↗
DirectMeds$249$3991Read the dossier →DirectMeds site ↗
GoodLife Health$299 membership+ brand-name drugNoneRead the dossier →GoodLife Health site ↗

Each row has two links: “Read the dossier” opens our file on that provider, and the “site ↗” button opens the provider’s own site in a new tab. Nothing else in the row is a link. Where a provider runs an affiliate programme with us, its site button is a referral link and we may earn a commission at no cost to you. It never changes the order or what is on file.

Straight answers

What the record does and does not say

Which GLP-1 telehealth companies have FDA warning letters or lawsuits against them?
78 of the 128 providers on this site have at least one sourced action on record, 88 in total. They are listed by provider above, and each action links to the document it came from.
Why has the FDA been sending warning letters about compounded GLP-1s?
Largely over marketing claims rather than the compounding itself. The FDA prohibits telehealth companies from describing a compounded drug as a generic version of, or the same as, an FDA-approved drug; from claiming it has been FDA-approved or evaluated for safety and effectiveness; and from implying it comes from an FDA-approved pharmacy, because the FDA does not approve or license compounding facilities. Roughly 85 warning letters went out between September 2025 and March 2026.
Does a company with an action against it still operate?
Almost all of them do. A warning letter is a demand to correct something, not a shutdown order, and several companies here responded by changing what they sell rather than by closing. That is precisely why a page saying only “this company got a letter” is worse than useless — what matters is what the letter said and what happened next.
How do I check any of this myself?
Follow the “Primary source” link under each entry. Every one goes to the document itself — an FDA warning letter on fda.gov, a court filing, a regulator's own announcement. If a claim on this site has no such link, it should not be here; tell us and we will remove it.
Cite This Enforcement Index · Open Public Record & Machine-Readable Feeds
Source: GLP-1 Dossier Editorial Desk (2026), “GLP-1 Telehealth Regulatory & Legal Enforcement Index (88 Actions),” https://glp1dossier.com/enforcement (Updated 16 November 2026).